Xilio Therapeutics (XLO) Insider Trading & Ownership

Xilio Therapeutics logo
$8.90 -0.04 (-0.45%)
Closing price 04:00 PM Eastern
Extended Trading
$8.94 +0.04 (+0.45%)
As of 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xilio Therapeutics (NASDAQ:XLO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
7.45%
Number Of
Insiders Buying
(Last 3 Years)
3
Amount Of
Insider Buying
(Last 3 Years)
$441.75K
Number Of
Insiders Selling
(Last 3 Years)
3
Amount Of
Insider Selling
(Last 3 Years)
$10.38K
Get XLO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XLO Insider Buying and Selling by Quarter

Xilio Therapeutics Insider and Congressional Trades History

Transaction DateInsiderBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2025
James Samuel Shannon
Director
Buy1,785$9.66$17,243.10  
6/16/2025
James Samuel Shannon
Director
Buy3,214$9.66$31,047.24  
6/16/2025
Rene Russo
CEO
Buy2,592$9.52$24,675.84  
1/2/2025
Christopher James Frankenfield
CFO
Sell496$13.72$6,805.12  
1/2/2025
Kevin M Brennan
SVP
Sell128$13.72$1,756.16  
4/2/2024
Gilead Sciences, Inc.
Major Shareholder
Buy34,660$10.64$368,782.40  
2/8/2024
Venture Fund Xi L.P. Atlas
Major Shareholder
Sell52$8.96$465.92  
1/11/2024
Venture Fund Xi L.P. Atlas
Major Shareholder
Sell111$12.18$1,351.98  
(Data available from 1/1/2013 forward)

XLO Insider Trading Activity - Frequently Asked Questions

The list of insiders at Xilio Therapeutics includes Christopher James Frankenfield, Gilead Sciences, Inc., James Samuel Shannon, Kevin M Brennan, Rene Russo, and Venture Fund Xi L.P. Atlas. Learn more on insiders at XLO.

7.45% of Xilio Therapeutics stock is owned by insiders. Learn more on XLO's insider holdings.

The following insiders have purchased XLO shares in the last 24 months: James Samuel Shannon ($48,290.34), and Rene Russo ($24,675.84).

Insiders have purchased a total of 7,591 XLO shares in the last 24 months for a total of $72,966.18 bought.

The following insiders have sold XLO shares in the last 24 months: Christopher James Frankenfield ($6,805.12), and Kevin M Brennan ($1,756.16).

Insiders have sold a total of 624 Xilio Therapeutics shares in the last 24 months for a total of $8,561.28 sold.



This page (NASDAQ:XLO) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners